FDA approves CSL Behring’s Idelvion to treat hemophilia B
Idelvion is the albumin fusion protein that links recombinant coagulation factor IX with recombinant albumin to treat hemophilia B. CSL Behring claims that the drug is the first
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the US focusing on branded products, 505(b)(2) medicines, and specialised generics.
Under the terms of the agreement, Ensemble is applying its drug discovery platform against several Alexion targets to discover new small molecule clinical candidates. Alexion will have exclusive
Spinocerebellar ataxia (SCA) is characterized clinically by progressive ataxia attributed to various etiologies. Ataxia is a complaint of loss of control of voluntary body movements and can involve